Browsing by Author "Monnet, Dominique L."
Now showing 1 - 8 of 8
Results Per Page
Sort Options
- Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysisPublication . Cassini, Alessandro; Högberg, Liselotte Diaz; Plachouras, Diamantis; Quattrocchi, Annalisa; Hoxha, Ana; Simonsen, Gunnar Skov; Colomb-Cotinat, Mélanie; Kretzschmar, Mirjam E.; Devleesschauwer, Brecht; Cecchini, Michele; Ouakrim, Driss Ait; Oliveira, Tiago Cravo; Struelens, Marc J.; Suetens, Carl; Monnet, Dominique L.; Strauss, Reinhild; Mertens, Karl; Struyf, Thomas; Catry, Boudewijn; Latour, Katrien; Ivanov, Ivan N.; Dobreva, Elina G.; Tambic Andraševic, Arjana; Soprek, Silvija; Budimir, Ana; Paphitou, Niki; Žemlicková, Helena; Schytte Olsen, Stefan; Wolff Sönksen, Ute; Märtin, Pille; Ivanova, Marina; Lyytikäinen, Outi; Jalava, Jari; Coignard, Bruno; Eckmanns, Tim; Abu Sin, Muna; Haller, Sebastian; Daikos, George L.; Gikas, Achilleas; Tsiodras, Sotirios; Kontopidou, Flora; Tóth, Ákos; Hajdu, Ágnes; Guólaugsson, Ólafur; Kristinsson, Karl G.; Murchan, Stephen; Burns, Karen; Pezzotti, Patrizio; Gagliotti, Carlo; Dumpis, Uga; Liuimiene, Agne; Perrin, Monique; Borg, Michael A.; de Greeff, Sabine C.; Monen, Jos C.M.; Koek, Mayke B.G.; Elstrøm, Petter; Zabicka, Dorota; Deptula, Aleksander; Hryniewicz, Waleria; Caniça, Manuela; Nogueira, Paulo Jorge; Fernandes, Paulo André; Manageiro, Vera; Popescu, Gabriel A.; Serban, Roxana I.; Schréterová, Eva; Litvová, Slavka; Štefkovicová, Mária; Kolman, Jana; Klavs, Irena; Korošec, Aleš; Aracil, Belén; Asensio, Angel; Pérez-Vázquez, María; Billström, Hanna; Larsson, Sofie; Reilly, Jacqui S.; Johnson, Alan; Hopkins, SusanBackground: Infections due to antibiotic-resistant bacteria are threatening modern health care. However, estimating their incidence, complications, and attributable mortality is challenging. We aimed to estimate the burden of infections caused by antibiotic-resistant bacteria of public health concern in countries of the EU and European Economic Area (EEA) in 2015, measured in number of cases, attributable deaths, and disability-adjusted life-years (DALYs). Methods: We estimated the incidence of infections with 16 antibiotic resistance–bacterium combinations from European Antimicrobial Resistance Surveillance Network (EARS-Net) 2015 data that was country-corrected for population coverage. We multiplied the number of bloodstream infections (BSIs) by a conversion factor derived from the European Centre for Disease Prevention and Control point prevalence survey of health-care-associated infections in European acute care hospitals in 2011–12 to estimate the number of non-BSIs. We developed disease outcome models for five types of infection on the basis of systematic reviews of the literature. Findings: From EARS-Net data collected between Jan 1, 2015, and Dec 31, 2015, we estimated 671 689 (95% uncertainty interval [UI] 583 148–763 966) infections with antibiotic-resistant bacteria, of which 63·5% (426 277 of 671 689) were associated with health care. These infections accounted for an estimated 33 110 (28 480–38 430) attributable deaths and 874 541 (768 837–989 068) DALYs. The burden for the EU and EEA was highest in infants (aged <1 year) and people aged 65 years or older, had increased since 2007, and was highest in Italy and Greece. Interpretation: Our results present the health burden of five types of infection with antibiotic-resistant bacteria expressed, for the first time, in DALYs. The estimated burden of infections with antibiotic-resistant bacteria in the EU and EEA is substantial compared with that of other infectious diseases, and has increased since 2007. Our burden estimates provide useful information for public health decision-makers prioritising interventions for infectious diseases.
- Carbapenemase-producing Enterobacteriaceaein Europe: assessment by national experts from 38 countries, May 2015Publication . Albiger, Barbara; Glasner, Corinna; Struelens, Marc J.; Grundmann, Hajo; Monnet, Dominique L.; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working groupIn 2012, the European Centre for Disease Prevention and Control (ECDC) launched the 'European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE)' project to gain insights into the occurrence and epidemiology of carbapenemase-producing Enterobacteriaceae (CPE), to increase the awareness of the spread of CPE, and to build and enhance the laboratory capacity for diagnosis and surveillance of CPE in Europe. Data collected through a post-EuSCAPE feedback questionnaire in May 2015 documented improvement compared with 2013 in capacity and ability to detect CPE and identify the different carbapenemases genes in the 38 participating countries, thus contributing to their awareness of and knowledge about the spread of CPE. Over the last two years, the epidemiological situation of CPE worsened, in particular with the rapid spread of carbapenem-hydrolysing oxacillinase-48 (OXA-48)- and New Delhi metallo-beta-lactamase (NDM)-producing Enterobacteriaceae. In 2015, 13/38 countries reported inter-regional spread of or an endemic situation for CPE, compared with 6/38 in 2013. Only three countries replied that they had not identified one single case of CPE. The ongoing spread of CPE represents an increasing threat to patient safety in European hospitals, and a majority of countries reacted by establishing national CPE surveillances systems and issuing guidance on control measures for health professionals. However, 14 countries still lacked specific national guidelines for prevention and control of CPE in mid-2015.
- Emergence of ST131 carrying carbapenemase genes, European Union/European Economic Area, August 2012 to May 2024Publication . Kohlenberg, Anke; Svartström, Olov; Apfalter, Petra; Hartl, Rainer; Bogaerts, Pierre; Huang, Te-Din; Chudejova, Katerina; Malisova, Lucia; Eisfeld, Jessica; Sandfort, Mirco; Hammerum, Anette M.; Roer, Louise; Räisänen, Kati; Dortet, Laurent; Bonnin, Rémy A.; Tóth, Ákos; Tóth, Kinga; Clarke, Christina; Cormican, Martin; Griškevičius, Algirdas; Khonyongwa, Kirstin; Meo, Marie; Niedre-Otomere, Baiba; Vangravs, Reinis; Hendrickx, Antoni Pa; Notermans, Daan W; Samuelsen, Ørjan; Caniça, Manuela; Manageiro, Vera; Müller, Vilhelm; Mäkitalo, Barbro; Kramar, Urška; Pirs, Mateja; Palm, Daniel; Monnet, Dominique L.; Alm, Erik; Linkevicius, MariusAnalysis of 594 isolates of sequence type (ST)131 and its single locus variants carrying carbapenemase genes from 17 European Union/European Economic Area countries revealed acquisition of 18 carbapenemase variants, mainly in ST131 clades A and C. Most frequent were (n = 230) and (n = 224), detected in 14 and 12 countries, respectively. Isolates carrying have increased rapidly since 2021. The increasing detection of carbapenemase genes in the high-risk lineage ST131 is a public health concern.
- Livestock-associated meticillin-resistantStaphylococcus aureus(MRSA) among human MRSA isolates, European Union/European Economic Area countries, 2013Publication . Kinross, Pete; Petersen, Andreas; Skov, Robert; Van Hauwermeiren, Evelyn; Pantosti, Annalisa; Laurent, Frédéric; Voss, Andreas; Kluytmans, Jan; Struelens, Marc J.; Heuer, Ole; Monnet, Dominique L.; The European human LA-MRSA study groupCurrently, surveillance of livestock-associated meticillin-resistantStaphylococcus aureus(LA-MRSA) in humans in Europe is not systematic but mainly event-based. In September 2014, the European Centre for Disease Prevention and Control (ECDC) initiated a questionnaire to collect data on the number of LA-MRSA from human samples (one isolate per patient) from national/regional reference laboratories in European Union/European Economic Area (EU/EEA) countries in 2013. Identification of LA-MRSA as clonal complex (CC) 398 by multilocus sequence typing (MLST) was preferred, although surrogate methods such asspa-typing were also accepted. The questionnaire was returned by 28 laboratories in 27 EU/EEA countries. Overall, LA-MRSA represented 3.9% of 13,756 typed MRSA human isolates, but it represented ≥ 10% in five countries (Belgium, Denmark, Spain, the Netherlands and Slovenia). Seven of the reference laboratories did not type MRSA isolates in 2013. To monitor the dispersion of LA-MRSA and facilitate targeted control measures, we advocate periodic systematic surveys or integrated multi-sectorial surveillance.
- Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational studyPublication . Grundmann, Hajo; Glasner, Corinna; Albiger, Barbara; Aanensen, David M.; Tomlinson, Chris T.; Andrasević, Arjana Tambić; Cantón, Rafael; Carmeli, Yehuda; Friedrich, Alexander W.; Giske, Christian G.; Glupczynski, Youri; Gniadkowski, Marek; Livermore, David M.; Nordmann, Patrice; Poirel, Laurent; Rossolini, Gian M.; Seifert, Harald; Vatopoulos, Alkiviadis; Walsh, Timothy; Woodford, Neil; Monnet, Dominique L.; EuSCAPE Working Group; Koraqi, A..; Lacej, D.; Apfalter, P.; Hartl, R.; Glupczynski, Y.; Huang, T.D.; Strateva, T; Marteva-Proevska, Y.; Tambic, Andrasevic A.; Butic, I.; Pieridou-Bagatzouni, D.; Maikanti-Charalampous, P.; Hrabak, J.; Zemlickova, H.; Hammerum, A.; Jakobsen, L.; Ivanova, M.; Pavelkovich, A.; Jalava, J.; Österblad, M.; Dortet, L.; Vaux, S.; Kaase, M.; Gatermann, S.G.; Vatopoulos, A.; Tryfinopoulou, K.; Tóth, A.; Jánvári, L.; Boo, T.W.; McGrath, E.; Carmeli, Y.; Adler, A.; Pantosti, A.; Monaco, M.; Raka, L.; Kurti, A.; Balode, A.; Saule, M.; Miciuleviciene, J.; Mierauskaite, A.; Perrin -Weniger, M.; Reichert, P.; Nestorova, N.; Debattista, S.; Mijovic, G.; Lopicic, M.; Samuelsen, Ø.; Haldorsen, B.J.; Żabicka, D.; Literacka, E.; Caniça, M.; Manageiro, V.; Kaftandzieva, A.; Trajkovska-Dokic, E.; Damian, M.; Lixandru, B.; Jelesic, Z.; Trudic, A.; Niks, M.; Schreterova, E.; Pirs, M.; Cerar, T.; Oteo, J.; Aracil, B.; Giske, C.; Sjöström, K.; Gür, D.; Cakar, A.; Woodford, N.; Hopkins, K.; Wiuff, C.; Brown, D.J.BACKGROUND: Gaps in the diagnostic capacity and heterogeneity of national surveillance and reporting standards in Europe make it difficult to contain carbapenemase-producing Enterobacteriaceae. We report the development of a consistent sampling framework and the results of the first structured survey on the occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in European hospitals. METHODS: National expert laboratories recruited hospitals with diagnostic capacities, who collected the first ten carbapenem non-susceptible clinical isolates of K pneumoniae or E coli and ten susceptible same-species comparator isolates and pertinent patient and hospital information. Isolates and data were relayed back to national expert laboratories, which made laboratory-substantiated information available for central analysis. FINDINGS: Between Nov 1, 2013, and April 30, 2014, 455 sentinel hospitals in 36 countries submitted 2703 clinical isolates (2301 [85%] K pneumoniae and 402 (15%) E coli). 850 (37%) of 2301 K pneumoniae samples and 77 (19%) of 402 E coli samples were carbapenemase (KPC, NDM, OXA-48-like, or VIM) producers. The ratio of K pneumoniae to E coli was 11:1. 1·3 patients per 10 000 hospital admissions had positive clinical specimens. Prevalence differed greatly, with the highest rates in Mediterranean and Balkan countries. Carbapenemase-producing K pneumoniae isolates showed high resistance to last-line antibiotics. INTERPRETATION: This initiative shows an encouraging commitment by all participants, and suggests that challenges in the establishment of a continent-wide enhanced sentinel surveillance for carbapenemase-producing Enterobacteriaeceae can be overcome. Strengthening infection control efforts in hospitals is crucial for controlling spread through local and national health care networks.
- Rapid cross-border emergence of NDM-5-producing Escherichia coli in the European Union/European Economic Area, 2012 to June 2022Publication . Linkevicius, Marius; Bonnin, Rémy A.; Alm, Erik; Svartström, Olov; Apfalter, Petra; Hartl, Rainer; Hasman, Henrik; Roer, Louise; Räisänen, Kati; Dortet, Laurent; Pfennigwerth, Niels; Hans, Jörg B.; Tóth, Ákos; Buzgó, Lilla; Cormican, Martin; Delappe, Niall; Monaco, Monica; Giufrè, Maria; Hendrickx, Antoni P.A.; Samuelsen, Ørjan; Pöntinen, Anna K.; Caniça, Manuela; Manageiro, Vera; Oteo-Iglesias, Jesús; Pérez-Vázquez, María; Westmo, Karin; Mäkitalo, Barbro; Palm, Daniel; Monnet, Dominique L.; Kohlenberg, AnkeWhole genome sequencing data of 874 Escherichia coli isolates carrying bla NDM-5 from 13 European Union/European Economic Area countries between 2012 and June 2022 showed the predominance of sequence types ST167, ST405, ST410, ST361 and ST648, and an increasing frequency of detection. Nearly a third (30.6%) of these isolates were associated with infections and more than half (58.2%) were predicted to be multidrug-resistant. Further spread of E. coli carrying bla NDM-5 would leave limited treatment options for serious E. coli infections.
- Strong correlation between the rates of intrinsically antibiotic-resistant species and the rates of acquired resistance in Gram-negative species causing bacteraemia, EU/EEA, 2016Publication . Jarlier, Vincent; Diaz Högberg, Liselotte; Heuer, Ole E.; Campos, José; Eckmanns, Tim; Giske, Christian G.; Grundmann, Hajo; Johnson, Alan P; Kahlmeter, Gunnar; Monen, Jos; Pantosti, Annalisa; Rossolini, Gian Maria; van de Sande-Bruinsma, Nienke; Vatopoulos, Alkiviadis; Żabicka, Dorota; Žemličková, Helena; Monnet, Dominique L.; Simonsen, Gunnar Skov; EARS-Net ParticipantsBackground: Antibiotic resistance, either intrinsic or acquired, is a major obstacle for treating bacterial infections.AimOur objective was to compare the country-specific species distribution of the four Gram-negative species Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter species and the proportions of selected acquired resistance traits within these species.MethodWe used data reported for 2016 to the European Antimicrobial Resistance Surveillance Network (EARS-Net) by 30 countries in the European Union and European Economic Area.ResultsThe country-specific species distribution varied considerably. While E. coli accounted for 31.9% to 81.0% (median: 69.0%) of all reported isolates, the two most common intrinsically resistant species P. aeruginosa and Acinetobacter spp. combined (PSEACI) accounted for 5.5% to 39.2% of isolates (median: 10.1%). Similarly, large national differences were noted for the percentages of acquired non-susceptibility to third-generation cephalosporins, carbapenems and fluoroquinolones. There was a strong positive rank correlation between the country-specific percentages of PSEACI and the percentages of non-susceptibility to the above antibiotics in all four species (rho > 0.75 for 10 of the 11 pairs of variables tested).ConclusionCountries with the highest proportion of P. aeruginosa and Acinetobacter spp. were also those where the rates of acquired non-susceptibility in all four studied species were highest. The differences are probably related to national differences in antibiotic consumption and infection prevention and control routines.
- Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018Publication . Brolund, Alma; Lagerqvist, Nina; Byfors, Sara; Struelens, Marc J.; Monnet, Dominique L.; Albiger, Barbara; Kohlenberg, Anke; European Antimicrobial Resistance Genes Surveillance Network (EURGen-Net) capacity survey group, Vera)A survey on the epidemiological situation, surveillance and containment activities for carbapenemase-producing Enterobacteriaceae (CPE) was conducted in European countries in 2018. All 37 participating countries reported CPE cases. Since 2015, the epidemiological stage of CPE expansion has increased in 11 countries. Reference laboratory capability, dedicated surveillance and a specific national containment plan are in existence in 33, 27 and 14 countries, respectively. Enhanced control efforts are needed for CPE containment in Europe.